STRATA Skin Sciences, Inc. (SSKN)

STRATA Skin Sciences makes machines that dermatologists use to treat skin problems. The company is small, focused, and has been around since 1989. It sells two main types of devices: lasers that treat psoriasis and vitiligo, and a system for treating acne. The company is based in Horsham, Pennsylvania, and sells its machines to dermatologists and skin-treatment clinics around the world. Think of STRATA like the company that builds the equipment your dermatologist uses — not the doctor or the clinic, but the equipment manufacturer that keeps the business running.

What STRATA actually makes and sells

The star product is XTRAC — a 308-nanometre excimer laser that shines UV light on skin. When dermatologists point this laser at psoriasis plaques or at patches of vitiligo (where skin loses pigment), the light can slow down the psoriasis or help pigment come back. Dermatologists use XTRAC in their offices; patients come in for regular treatments, and each treatment is billed to insurance or paid out of pocket. The company sells the machines to clinics and dermatology practices. Then, every time a doctor uses the machine, STRATA gets a cut of the procedure fee, or the clinic buys consumables (parts that wear out or break) from STRATA. This two-step revenue model — sell the machine once, then get paid every time it is used — is the classic playbook for medical-device companies.

VTRAC is a lamp-based system that does similar work but is cheaper and less versatile than the laser. TheraClear is a different type of machine that treats acne by combining light and heat. All three products do the same essential job: bring a dermatologist’s patients in regularly, do a procedure, charge them or their insurance, and keep the equipment maintained through STRATA.

How the business actually works

STRATA sells these machines through a direct sales force and through distributors. A dermatology practice buys an XTRAC machine for somewhere in the range of tens of thousands of dollars (the exact price is not public, but it is not cheap). The clinic now owns a piece of equipment that it needs to operate, maintain, and eventually replace. STRATA makes money on the sale, but the real money comes next: every time the clinic runs a procedure, STRATA either gets a percentage of the fee (a revenue-sharing arrangement) or the clinic pays an annual subscription or licensing fee to use the machine.

The acne and vitiligo and psoriasis treatment market is not huge, but it is steady. Psoriasis affects roughly 2 to 3 percent of the population in developed countries. Vitiligo is rarer, maybe 0.5 to 1 percent. Acne is common. None of these conditions kill you, but they cause real distress, and people seek treatment. Dermatologists are incentivised to offer good treatments because their patients demand them and because insurance often pays. This stability is why STRATA has survived and stayed profitable long enough to go public.

The two sides of the business

STRATA splits its revenue into two segments. Dermatology Recurring Procedures is the everyday business: dermatologists own XTRAC machines, use them, send patients in regularly, and STRATA captures a slice of each procedure. This segment is the steady-Eddie part of the business. Dermatology Procedures Equipment is the sale of new machines and upgrades. When a clinic decides to buy its first XTRAC or replace an old one with a new model, that is equipment revenue. Equipment sales are lumpy — some quarters are strong, others are weak — but they represent the cash infusion that funds operations.

The balance between these two segments matters. If recurring procedures are declining, it means dermatologists are using XTRAC machines less, which could signal market saturation or competition from newer technologies. If equipment sales fall, it could mean clinics are happy with older machines or are switching to competitors. Both matter.

Competition and market dynamics

STRATA competes against other manufacturers of dermatology equipment. The market is not huge, so there are not dozens of competitors, but there are enough that STRATA has to keep innovating and investing in sales and marketing. Larger medical-device companies might decide to enter the dermatology space or acquire a competitor. Newer, potentially more effective technologies could emerge. Insurance companies might decide that some dermatology treatments are not worth paying for, which would kill demand. All of these things are real risks.

One advantage STRATA has is that it has been in this space since 1989. Dermatologists know the XTRAC brand. Clinics have invested in these machines and trained staff on them. There is switching cost — if you own an XTRAC, you are somewhat locked in to buying consumables and upgrades from STRATA. This is a modest moat, but it exists.

Geographic spread and regulatory challenges

STRATA sells machines in North America, Europe, Asia, the Middle East, Australia, and South Africa. This geographic spread helps because it means the company is not dependent on any single market or economy. If the US market is slow, European demand might be strong. The flip side is complexity: each country has different rules about medical devices, different insurance systems, and different regulatory requirements. The European Union, for instance, has strict rules about what medical devices can claim, and regulators in each country can block or limit the use of a device.

Medical devices also face liability risk. If someone is injured or harmed by an XTRAC machine, they might sue STRATA. The company carries insurance and has legal defences, but major lawsuits can be expensive and damaging to reputation.

Recent changes and the path forward

In 2026, STRATA notified investors that it was suspending trading on Nasdaq and preparing to delist. The company said this decision would reduce the cost and burden of being a public company, allowing management to focus on operations instead of regulatory filings and investor relations. Going private, either through a buyout or staying public on smaller exchanges, changes the capital structure and the expectations around growth and profitability.

The fundamentals of the dermatology business have not changed: patients still get psoriasis, vitiligo, and acne; dermatologists still treat them; clinics still need equipment. But the company’s ability to fund growth, invest in new products, or acquire competitors becomes more constrained if it loses access to public capital markets. This shift is a sign that STRATA is focusing on what it does best — building and selling dermatology equipment — rather than pursuing aggressive growth.

How to research STRATA

To understand STRATA, start with its SEC filings (CIK 0001051514). Look for trends in recurring procedure revenue (up or down?) and equipment sales (growing or shrinking?). The quarterly earnings reports should break down revenue by geography and by segment, showing where growth is and where it is stalling. Watch for any announcements about new product launches or clinical studies proving the effectiveness of XTRAC or TheraClear — these matter because they drive demand. If STRATA announces a new competitor or a technology that might replace its machines, that is worth paying attention to. Finally, keep an eye on regulatory changes. If a major insurance company stops paying for psoriasis laser treatment, or if a regulator bans a device, that changes the game. As always, the share price is set by the market, and this explanation is just a map of how the business works.